HeartBeam to Report Q1 2026 Earnings, Update on Commercial Launch and AI Programs

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss first-quarter results for the period ended March 31, 2026, and provide updates on key growth initiatives. These include its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection, and AI programs.

The company, based in Los Angeles, is developing a cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable use, enabling physicians to identify cardiac health trends and acute conditions outside a medical facility. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received clearance in December 2025.

The upcoming call comes as HeartBeam progresses toward commercializing its core technology. The limited commercial launch for arrhythmia assessment marks a significant step in bringing its platform to market. Meanwhile, the development of an extended-wear patch could expand the company’s product line for continuous monitoring. HeartBeam is also advancing heart attack detection capabilities and AI programs, which could enhance diagnostic accuracy and clinical decision-making.

The implications of these developments are substantial. If successful, HeartBeam’s technology could shift cardiac monitoring from hospital-based settings to home and remote environments, potentially reducing healthcare costs and improving patient outcomes. The ability to detect arrhythmias and heart attacks early with a portable device addresses a critical need in cardiovascular care, where timely intervention is often life-saving.

For investors, the earnings call will provide insight into the company’s financial health and the traction of its commercial launch. As of the press release, HeartBeam holds over 20 issued patents related to its technology. More information is available in the company’s newsroom at https://ibn.fm/BEAT. The full press release can be accessed at https://ibn.fm/yN939.

The company cautions that forward-looking statements in the announcement involve risks and uncertainties, as detailed in its SEC filings. The call will be webcast, and details are expected to be released closer to the date.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is HeartBeam to Report Q1 2026 Earnings, Update on Commercial Launch and AI Programs.

The post HeartBeam to Report Q1 2026 Earnings, Update on Commercial Launch and AI Programs appeared first on citybuzz.